Yuhong Zeng

Yuhong Zeng

Auto-generated profile, based on publicly available information

Yuhong Zeng

Department of Epidemiology, College of Preventive Medicine Army Medical University (Third Military Medical University) Chongqing People's Republic of China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
YZYuhong Zeng
Yuhong Zeng
NWNa Wu
Na Wu
ZZZhi-Hui Zhang
Zhi-Hui Zhang
LZLi Zhong
Li Zhong
GLGuowei Li
Guowei Li
YLYafei Li
Yafei Li
Arrhythmias are a class of cardiac dysfunction characterized by heart rate disturbances and heart rhythm abnormalities, which are associated with substantial morbidity and mortality. Due to the limited understanding of pathological mechanism, current antiarrhythmic drugs and invasive therapies on arrhythmias lack sufficient efficacy and are always accompanied by potential adverse effects. Non-coding RNAs (including microRNAs, long non-coding RNAs, circular RNAs, and other small non-coding RNAs) have been demonstrated to be involved in the occurrence and development of various diseases including arrhythmias, which opens a new prospect for exploring the mechanism of arrhythmias and developing new therapeutic targets. Therefore, in this review, we aimed to provide an overview of the expression of ncRNAs in various arrhythmias, their roles in the arrhythmia’s development and pathophysiology, and the potential mechanism of ncRNAs in arrhythmias. As atrial fibrillation (AF) is the most common arrhythmia in clinical practice and current studies mainly focus on it, this review primarily discussed about AF. It was expected that this review may provide a basis for a better understanding of the mechanistic role of ncRNAs in arrhythmias and facilitate the development of mechanic-based therapeutic targets.

22 June 2024 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
YZYuhong Zeng
Yuhong Zeng
ZYZhiquan Yuan
Zhiquan Yuan
JLJun Li
Jun Li
LYLanqing Yang
Lanqing Yang
CLChengying Li
Chengying Li
NWNa Wu
Na Wu
The development of high‐throughput technologies has enhanced our understanding of small non‐coding RNAs (sncRNAs) and their crucial roles in various diseases, including atrial fibrillation (AF). This study aimed to systematically delineate sncRNA profiles in AF patients. PANDORA‐sequencing was used to examine the sncRNA profiles of atrial appendage tissues from AF and non‐AF patients. Differentially expressed sncRNAs were identified using the R package DEGseq 2 with a fold change >2 and p < 0.05. The target genes of the differentially expressed sncRNAs were predicted using MiRanda and RNAhybrid. Gene Ontology (GO) categories and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed. In AF patients, the most abundant sncRNAs were ribosomal RNA‐derived small RNAs (rsRNAs), followed by transfer RNA‐derived small RNAs (tsRNAs), and microRNAs (miRNAs). Compared with non‐AF patients, 656 rsRNAs, 45 miRNAs, 191 tsRNAs and 51 small nucleolar RNAs (snoRNAs) were differentially expressed in AF patients, whereas no significantly differentially expressed piwi‐interacting RNAs were identified. Two out of three tsRNAs were confirmed to be upregulated in AF patients by quantitative reverse transcriptase polymerase chain reaction, and higher plasma levels of tsRNA 5006c‐LysCTT were associated with a 2.55‐fold increased risk of all‐cause death in AF patients (hazard ratio: 2.55; 95% confidence interval, 1.56–4.17; p < 0.001). Combined with our previous transcriptome sequencing results, 32 miRNA, 31 snoRNA, 110 nucleus‐encoded tsRNA, and 33 mitochondria‐encoded tsRNA target genes were dysregulated in AF patients. GO and KEGG analyses revealed enrichment of differentially expressed sncRNA target genes in AF‐related pathways, including the ‘calcium signaling pathway’ and ‘adrenergic signaling in cardiomyocytes.’ The dysregulated sncRNA profiles in AF patients suggest their potential regulatory roles in AF pathogenesis. Further research is needed to investigate the specific mechanisms of sncRNAs in the development of AF and to explore potential biomarkers for AF treatment and prognosis.

21 June 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
YMYuanqi Mi
Yuanqi Mi
YZYuhong Zeng
Yuhong Zeng
PWPeicheng Wang
Peicheng Wang
MZMengge Zhou
Mengge Zhou
FCFeng Cheng
Feng Cheng
Objective: Men who have sex with men in China meet the definition of the population at “substantial risk” of contracting human immunodeficiency virus (HIV) according to the World Health Organization; therefore, initiating pre-exposure prophylaxis (PrEP) is recommended for this population. Lack of convincing evidence on cost-effectiveness has resulted in the lack of large-scale PrEP implementation at a national level. The objective of this review is to assess the cost-effectiveness of pre-exposure prophylaxis implementation among men who have sex with men in China.Methods: The following databases were used to search studies of pre-exposure prophylaxis in China in both English and Chinese: PubMed, Embase, the China National Knowledge Infrastructure (CNKI), and the Wanfang Database. Inclusion criteria included pre-exposure intervention, year for publication (2007–2021), setting (China), and cost-effectiveness estimation.Results: Seven studies were identified. We found that pre-exposure prophylaxis is only cost-effective among men who have sex with men without prioritization with at least a 5.5% reduction in the market price in the models. Pre-exposure prophylaxis is potentially cost-effective when using the latest market price, combined with other preventive programs or delivered to the population with a high risk of HIV exposure.Conclusion: Our study identifies key considerations in cost-effectiveness evaluation: cost assumptions, implementation coverage, and targeted population. The scarce evidence available is not comparable to some extent. However, combined with the latest market and policy reform, the cost-effectiveness of PrEP could be achieved as estimated by the underlying model of the included studies. Consequently, it calls for more standard and transparent modeling studies that include the latest drug types and market prices.